Voiding recovery after radical parametrectomy in cervical cancer patients: An international prospective multicentre trial - SENTIX.


Journal

Gynecologic oncology
ISSN: 1095-6859
Titre abrégé: Gynecol Oncol
Pays: United States
ID NLM: 0365304

Informations de publication

Date de publication:
03 2021
Historique:
received: 24 10 2020
accepted: 15 12 2020
pubmed: 10 1 2021
medline: 5 8 2021
entrez: 9 1 2021
Statut: ppublish

Résumé

Voiding dysfunctions represent a leading morbidity after radical hysterectomy performed in patients with early-stage cervical cancer. The aim of this study was to perform ad hoc analysis of factors influencing voiding recovery in SENTIX (SENTinel lymph node biopsy in cervIX cancer) trial. The SENTIX trial (47 sites, 18 countries) is a prospective study on sentinel lymph node biopsy without pelvic lymphadenectomy in patients with early-stage cervical cancer. Overall, the data of 300 patients were analysed. Voiding recovery was defined as the number of days from surgery to bladder catheter/epicystostomy removal or to post-voiding urine residuum ≤50 mL. The median voiding recovery time was three days (5th-95th percentile: 0-21): 235 (78.3%) patients recovered in <7 days and 293 (97.7%) in <30 days. Only seven (2.3%) patients recovered after >30 days. In the multivariate analysis, only previous pregnancy (p = 0.033) and type of parametrectomy (p < 0.001) significantly influenced voiding recovery >7 days post-surgery. Type-B parametrectomy was associated with a higher risk of delayed voiding recovery than type-C1 (OR = 4.69; p = 0.023 vs. OR = 3.62; p = 0.052, respectively), followed by type-C2 (OR = 5.84; p = 0.011). Both previous pregnancy and type C2 parametrectomy independently prolonged time to voiding recovery by two days. Time to voiding recovery is significantly related to previous pregnancy and type of parametrectomy but it is not influenced by surgical approach (open vs minimally invasive), age, or BMI. Type B parametrectomy, without direct visualisation of nerves, was associated with longer recovery than nerve-sparing type C1. Importantly, voiding dysfunctions after radical surgery are temporary, and the majority of the patients recover in less than 30 days, including patients after C2 parametrectomy.

Identifiants

pubmed: 33419610
pii: S0090-8258(20)34221-9
doi: 10.1016/j.ygyno.2020.12.018
pii:
doi:

Types de publication

Journal Article Multicenter Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

729-734

Informations de copyright

Copyright © 2020 Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Conflict of interest statement Authors do not have any conflicts of interest.

Auteurs

Ignacio Zapardiel (I)

Gynaecologic Oncology Unit, La Paz University Hospital-IdiPAZ, Madrid, Spain. Electronic address: ignaciozapardiel@hotmail.com.

Roman Kocian (R)

Gynaecologic Oncology Centre, Department of Obstetrics and Gynaecology, First Faculty of Medicine, Charles University and General University Hospital, CEEGOG, Prague, Czech Republic.

Cristhardt Köhler (C)

Department of Special Operative and Oncologic Gynaecology, Asklepios-Clinic Hamburg, Hamburg, Germany.

Jaroslav Klat (J)

Department of Obstetrics and Gynaecology, University Hospital Ostrava, Ostrava, Poruba, Czech Republic.

Anna Germanova (A)

Gynaecologic Oncology Centre, Department of Obstetrics and Gynaecology, First Faculty of Medicine, Charles University and General University Hospital, CEEGOG, Prague, Czech Republic.

Anna Jacob (A)

Department of Special Operative and Oncologic Gynaecology, Asklepios-Clinic Hamburg, Hamburg, Germany.

Sylva Bajsova (S)

Department of Obstetrics and Gynaecology, University Hospital Ostrava, Ostrava, Poruba, Czech Republic.

Gerd Böhmer (G)

Department of Special Operative and Oncologic Gynaecology, Asklepios-Clinic Hamburg, Hamburg, Germany.

Laura Lay (L)

Department of Gynaecology, Institute of Oncology Angel H Roffo University of Bueno s Aires, Buenos Aires, Argentina.

Blanca Gil-Ibañez (B)

Unit of Gynaecological Oncology, Institute Clinic of Gynaecology, Obstetrics and Neonatology (ICGON), Hospital Clinic of Barcelona, Barcelona, Spain.

Pavel Havelka (P)

Department of Obstetrics and Gynaecology, Bata Hospital Zlin, Czech Republic, CEEGOG, Zlin, Czech Republic.

Barbara Kipp (B)

Department of Obstetrics and Gynaecology, Cantonal Hospital of Lucerne, Lucerne, Switzerland.

Grzegorz Szewczyk (G)

Department of Obstetrics and Gynaecology, Institute of Mother and Child, Warsaw, Poland.

Robert Toth (R)

Oncology Institute of East Slovakia, Košice, Slovakia.

Juan Carlos Staringer (JC)

Department of Gynaecology and Obstetrics, Hospital Español de Buenos Aires, Buenos Aires, Argentina.

Javier De Santiago (J)

Gynecologic Oncology Unit, MD Anderson Cancer Centre, Madrid, Spain.

Pluvio J Coronado (PJ)

Departamento de Obstetricia y Ginecología, Hospital Clínico San Carlos, Madrid, Spain.

Robert Poka (R)

Institute of Obstetrics and Gynaecology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.

Rene Laky (R)

Gynaecology, Medical University of Graz, Graz, Austria.

Mathieu Luyckx (M)

Department of Gynaecology, Universite catholique de Louvain, Cliniques Universitaires St Luc, 1200, Brussels, Belgium.

Maxime Fastrez (M)

Department of Obstetrics and Gynaecology, St Pierre University Hospital, Université Libre de Bruxelles, Brussels, Belgium.

Ladislav Dusek (L)

Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Brno, Czech Republic.

Alicia Hernandez (A)

Gynaecologic Oncology Unit, La Paz University Hospital-IdiPAZ, Madrid, Spain.

David Cibula (D)

Gynaecologic Oncology Centre, Department of Obstetrics and Gynaecology, First Faculty of Medicine, Charles University and General University Hospital, CEEGOG, Prague, Czech Republic.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH